Isa-VRd vs VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (IMROZ)

Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) versus VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (IMROZ)

Summary:
The Phase 3 IMROZ study compared the efficacy and safety of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). The study included 446 patients and the primary endpoint was progression-free survival (PFS). The results showed that Isa-VRd significantly reduced the risk of progression or death by 40.4% compared to VRd. Isa-VRd also led to deep and sustained responses, with higher rates of complete response (CR), minimal residual disease negativity (MRD-), and sustained MRD-for at least 12 months. The safety profile of Isa-VRd was consistent with the addition of isatuximab to VRd. These findings support Isa-VRd as a potential new standard of care for transplant-ineligible NDMM patients.

Key Points:
1. The Phase 3 IMROZ study compared the efficacy and safety of Isa-VRd versus VRd in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
2. Isa-VRd significantly reduced the risk of progression or death by 40.4% compared to VRd.
3. Isa-VRd led to higher rates of complete response (CR) compared to VRd.
4. Isa-VRd also resulted in higher rates of minimal residual disease negativity (MRD-) compared to VRd.
5. Sustained MRD-for at least 12 months was achieved in a higher percentage of patients treated with Isa-VRd compared to VRd.
6. The safety profile of Isa-VRd was consistent with the addition of isatuximab to VRd.
7. Grade 3 treatment-emergent adverse events (TEAEs) were reported in a higher percentage of patients treated with Isa-VRd compared to VRd.
8. Grade 5 TEAEs were reported in a higher percentage of patients treated with Isa-VRd compared to VRd.
9. The percentage of patients experiencing any TEAE leading to definitive treatment discontinuation was similar between Isa-VRd and VRd treatment groups.

Authors:
Thierry Facon, Meletios Athanasios Dimopoulos, Xavier P Leleu, Meral Beksac, Ludek Pour, Roman Hajek, Zhuogang Liu, Jiri Minarik, Philippe Moreau, Joanna Romejko-Jarosinska, Ivan Spicka, Vladimir I. Vorobyev, Michele Cavo, Hartmut Goldschmidt, Thomas G. Martin, Salomon Manier, Marie-France Bregeault, Sandrine Mace,Christelle Berthou, Robert Z. Orlowski

Clinical Trial Registration Number: NCT03319667
Abstract# 7500
DOI: 10.1200/JCO.2024.42.16_suppl.7500

_______________
Improving Lives | Finding the Cure

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel:    / imfmyeloma  

Visit our website at: https://www.myeloma.org

Find us online:
Facebook: @myeloma |   / myeloma  
Twitter: @IMFMyeloma |   / imfmyeloma  
Instagram: @imfmyeloma |   / imfmyeloma  
LinkedIn:   / international-myeloma-foundation  

Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52...

Category
Nonprofits & Activism
License
Standard YouTube License

In most cases, captions are autogenerated by YouTube.